US/UK/Canada

Share

Contacts

  • Jenny Styren

    Chief Marketing & Communication Officer


    +46 703793483

    • Quotes

    We are truly excited about the possibilities of being able to welcome FRISQ, its employees, partners and customers to Cambio. The portfolio of FRISQ will fill a very important part of our offering going forward but more importantly we will add lots of new, fantastic talent across the board of our business. Now our focus will be on completing the Due Diligence and conclude the transaction during Q3
    Rami Avidan, CEO, Cambio
    Pick a time period -
    Tags ( Active)

    Cambio receives MDR certification for EHR-system and clinical decision support

    Cambio's electronic health record system Cosmic and their solution for clinical decision support (CDS) have now been registered and certified according to MDR, the Medical Device Regulation. This means that the products are approved and CE-marked in accordance with the EU regulation on medical devices, which ensures the safety and performance of medical equipment. "The MDR certification is an important milestone for us as a company, and I am very proud of the work we have done together at Cambio. The certification is proof that those who use our products can trust that they meet the

    Cambio Interim Report Q2 2024

    The previous quarter held a lot of progress for us at Cambio. Getting the confidence from Åland to be a part of their coming journey in healthcare with delivering our EHR-system Cosmic is a great testament to our strong offering to the market. Soon we will start off with the first of the Sussa regions to go live with Cambio Cosmic. Region Örebro will be the first of nine Swedish regions. Im humbled and proud over the fact that soon a majority of the healthcare provided in Sweden will be provided through Cambio COSMIC. At Cambio we continue to develop solutions, partnerships and innovation

    Sanolium interim report Q1 Jan-Mar 2024

    Today Sanolium releases the interim report for the first quarter this year“We have continued developing the company in line with our strategic direction during the first quarter 2024. Im proud to see such progress among our ongoing projects as well as the trust from new customers as we continue on the journey towards a healthier tomorrow,” says Rami Avidan, CEO of Cambio A number of important steps has been taken during Q1: · Frame agreement with Karolinska Institute · Continued preparations for the go live with Sussa, one of the largest IT healthcare projects in Europe ·

    Sanolium publishes bond prospectus and applies for listing of its bonds on Nasdaq Stockholm

    Sanolium AB (publ) (the "Company" or "Sanolium") has issued a senior secured bond loan of SEK 1,000,000,000 on 15 March 2024, within a total framework amount of SEK 1,500,000,000, on the Swedish bond market (the "Bonds"). The Bonds carry a floating interest rate of STIBOR 3m + 4.00 per cent. per annum and matures 15 March 2029. The Company will apply for listing of the Bonds on the Corporate Bond list at Nasdaq Stockholm. The Bonds will be admitted to trading at Nasdaq Stockholm as soon as possible. In connection with this, the Company has prepared a prospectus. The prospectus has

    Sanolium announces that the condition for the early redemption of its outstanding 2019/2024 bonds has been satisfied

    On 29 February 2024, Sanolium AB (publ) (the "Company" or "Sanolium") announced its intention to redeem in full the outstanding 2019/2024 bonds with ISIN SE0012596179 (the "Redemption" and the "Existing Bonds", respectively).The Redemption was conditional upon the Issuer's receipt of funds in connection with the issue of new floating rate senior secured bonds under a total framework of SEK 1,500 million, with a tenor of five years and an initial amount of SEK 1,000 million, as further described in the Company's press release on 29 February 2024 (the "Financing Condition" and the "New Bonds",

    Sanolium successfully announces results from the tender offer

    NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAWSanolium AB (publ) (the “Company” or “Sanolium”), being the parent company of the Cambio group, announces results of its tender offer (the “Tender Offer”) to the holders of Sanolium’s

    Sanolium successfully issued new senior secured bonds of SEK 1,000m

    NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAWSanolium AB (publ) (the “Company” or “Sanolium”), being the parent company of the Cambio group, has successfully issued senior secured bonds (the “New Bonds”) in an initial amount of SEK 1,

    Cambio Year End Report Q4 2023

    We had a strong fourth quarter, characterized by solid profitable growth and important customer wins. Customer Group KGC (Kundgrupp Cosmic), which consists of eight Swedish regions and one private care giver, has signed an extension of its COSMIC contract for another 5 years with 3 additional option years. This is a testament to the strong relationship between KGC and Cambio that has been developed over the last years. In the fourth quarter, we received a major order worth 84 MSEK to provide additional functionality to KGC, which will be delivered during 2023 and 2024. The order

    Sanolium contemplates issuance of new senior secured bonds, announces a conditional tender offer for its outstanding 2019/2024 bonds and gives a conditional call notice of early redemption

    NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW Sanolium AB (publ) (the “Company” or “Sanolium”) has mandated DNB Markets, a part of DNB Bank ASA, Sweden Branch as Global Coordinator and Joint Bookrunner and Carnegie Investment Bank AB (

    Interim report Q3 2023

    Growing demand for our solutions reflects the need for increased digitalization in health- and social care. The Nordic regions and municipalities need to invest more in IT than they have done historically. Cambio has the products and services to bridge the technical gap that the regions and municipalities face, and to enable tomorrow’s health- and social care. Together with our customers, we contribute to a better and healthier society.Revenue in the third quarter amounted to 256.4 MSEK, representing a growth of 28.8% Q3, July - September January - September 20232023 ·

    KGC regions extends agreement regarding support and maintenance of the electronic health record system Cambio COSMIC

    The agreement between the regions within Client group Cosmic (KGC) and Cambio Healthcare Systems AB (Cambio) regarding support and maintenance of the electronic health record system Cambio COSMIC (Cosmic) is extended, starting on 1 January 2024. The agreement runs for five years, with the possibility of extension for a further three years.KGC consists of eight regions and the privately owned Capio St. Göran's hospital, each of which has individually chosen Cosmic as its electronic health record system. KGC was formed in 2007 to give the regions and Capio S:t Göran the conditions to, in

    Region Syddanmark chooses Cambio to deliver their CIS PDMS solution for critical care

    Region Syddanmark has again selected Cambio, in partnership with Atea to continue with the provision of their CIS PDMS solution. The Cambio CIS solution, remains the regions ‘Best of Breed’ solution of choice, for use in all ICU and selected anesthesia departments in the region.The Region will standardise their use of Cambio CIS across the region and will also base the key medical device data collection on its MDIC (Cambio CDC) platform, used to collect, store and distribute high resolution data. The details of the tender also support the potential rollout of the solution in all anesthesia,

    Sanolium AB interim report April - June 2023

    Revenue in the second quarter amounted to 273.0 MSEK, representing a growth of 24.4%CEO´s comment Cambio continues to take steps on the journey to implement our strategy and to digitize health and social care in our prioritized markets. The second quarter has been characterized by continued build-up of our business within key customer groups. For Sussa Samverkan, one of our major customer groups consisting of 9 Swedish regions, we have passed the Acceptance Test 2 in April, meaning that our solution has had the final acceptance from our customers. This means that we can now continue

    Sanolium AB interim report, January - March 2022

    CEO’s Comments Growing demand for our solutions reflects the need for increased digitalization in health and social care. The Nordic regions and municipalities need to invest more in IT than they have done historically. Cambio has the products and services to bridge the technical gap that the regions and municipalities face, and to enable tomorrow’s health and social care. Together with our customers, we contribute to a better and healthier society. [Read more in the full report] Revenue in the first quarter amounted to 244.1 MSEK, representing a growth of 18.9% Q1,

    Sanolium interim report Q4 oct-dec 2022

    Cambio is well positioned to become the Nordic leader within eHealth. Today we serve Nordic regions, municipalities, and private healthcare provi-ders by delivering their core healthcare IT system.Revenue in the fourth quarter amounted to 223.6 MSEK, representing a growth of 14.1% Q4, October - December 2022 January - December 2022 · Revenue amounted to 223.6 (196.0) MSEK in · Revenue December YTDthe fourth quarter, representing a growth of amounted to 847.514.1% (790.6) MSEK · Adjusted EBITDA

    Sanolium AB interim report, July – September 2022

    Cambio constitutes the operating entities under Sanolium AB. All figures in () refer to the comparable figures from previous year. Full-year 2018 and 2019 until February 20th includes the relevant operating entities pro forma, as that is prior to the establishment of Sanolium AB.   In the report regarding Q3, 2021 there was a restatement of error. The amounts in the comparison columns are corrected numbers. Revenue in the third quarter amounted to 199.1 MSEK, representing a growth of 4.0%. Q3, July - September 2022 · Revenue amounted to 199.1 (191.4) MSEK in the third quarter,

    Cambio strengthens position as market leader by acquiring FRISQ AB

    Cambio has a market leading position on the Swedish ehealth market and are now furter expanding their offer by acquiering FRISQ AB. FRISQ AB develops and delivers a digital care process support tool that simplifies for the care personal, supports a more effective way of working within the care team and creates new opportunities for the patient to be active in his or hers treatment.FRISQ develop a scalable software solution for interactive communication between different actors in the care chain – primarily through the software solution FRISQ Care. The software solution FRISQ Care enables

    Sanolium AB interim report, April – June 2022

    Revenue in the second quarter amounted to 219.5 (195.8) MSEK, representing an increase of 12.1%. Support and maintenance fees constitute the largest share of the revenue. License revenue and Professional Services revenue are attributable to the development of the existing product as well as the Sussa project. Adjusted EBITDA in the second quarter amounted to 61.0 (46.1) MSEK resulting in an adjusted EBITDA margin of 27.8 (23.5) %. Employee related expenses amounted to 123.1 (117.8) MSEK, representing an increase of 4.5 %. The number of full time equivalents (FTE) was 702 at the end of

    Cambio and FRISQ enters into a formal exclusive process to divest FRISQ to Cambio with a target transaction date in September 2022

    FRISQ board has decided to enter into a formal exclusive process with the objective to divest its operative business to Cambio Healthcare System AB (“Cambio”).  After several months of exploring the best options to secure the continued development of FRISQ, the Board of Directors of FRISQ Holding AB has decided to accept a proposal from Cambio. Both parties see large synergies in a potential deal and are optimistic about achieving a successful transaction.The proposal is to enter into an exclusive process to finalize the necessary due diligence required by Cambio, with the objective to

    Sanolium AB interim report, January - March 2022

    Revenue in the first quarter amounted to 205.3 (206.7) MSEK, representing a decrease of -0.7%Revenue in the first quarter amounted to 205.3 (206.7) MSEK, representing a decrease of -0.7%. Support and maintenance fees constitute the largest share of the revenue. License revenue and Professional Services revenue are attributable to the development of the existing product as well as the Sussa project. Adjusted EBITDA in the first quarter amounted to 58.2 (74.6) MSEK resulting in an adjusted EBITDA margin of 28.3 (36.1) %. Employee related expenses amounted to 111.6 (105.3) MSEK,

    Johannes Fabó new Chief Financial Officer at Cambio

    Cambio has appointed Johannes Fabó as Chief Financial Officer. Johannes, who will join Cambio effective 15[th] of August 2022, will also be a member of the Group Leadership Team.Johannes Fabó has had multiple roles within Finance, Controlling, PMO and Strategy Development within Munters, during its time both as a Private Equity-owned company and as a listed business on the Nasdaq Stockholm Large Cap stock exchange. He has also been a Board member of XM Reality, a First North listed company, and he started his career at the Boston Consulting Group. · I am pleased to welcome Johannes

    Sanolium Interim report 4/2021

    Revenues in the fourth quarter amounted to 196.6 MSEK, representing growth of 17.6%Support and maintenance fees constitute the largest share of the revenue. License revenues and Professional Services revenues are attributable to the development of the existing product as well as the Sussa project. Adjusted EBITDA in the fourth quarter amounted to 28.3 (12.2) MSEK resulting in an adjusted EBITDA margin of 14.4 (7.3) %. Employee related expenses amounted to 136.3 (129.3) MSEK, representing an increase of 5.4%. The number of full-time employees rose to 747 in the fourth quarter, an

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media

    Rss